Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2025 · The Lancet · 90 citations
https://doi.org/10.1016/s0140-6736(24)02722-3
A
Anwen Xiong
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
59
Papers
1.9K
Citations
19
h-index
31
i10-index
Anwen Xiong is an academic researcher from Tongji University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Immunotherapy and Biomarkers & Lung Cancer Research Studies. The author has an h-index of 19, co-authored 51 publications.
Papers by this author
worksImmune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study
2022 · Therapeutic Advances in Medical Oncology · 14 citations
https://doi.org/10.1177/17588359221136759
Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study
2024 · Journal of Hematology & Oncology · 13 citations
https://doi.org/10.1186/s13045-024-01651-5
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat